Peginterferon alfa-2a

Peginterferon alfa-2a (Ro 25-8310/000) is a 40 kDa branched pegylated IFN alfa-2a with antiviral and immunomodulatory activities. Peginterferon alfa-2a binds to the Interferon Receptor on the surface of target cells, induces the formation of ISGF3, and promotes the expression of effector proteins such as interferon-stimulated genes (ISGs) and Mx proteins, thereby exerting sustained antiviral effects. Peginterferon alfa-2a is applicable to research on virus infections associated with chronic hepatitis C and chronic hepatitis B^[1][2]. In Vitro:Peginterferon alfa-2a (Ro 25-8310/000) promotes the formation of ISGF3 by binding to Interferon Receptor on the surface of target cells, and induces the expression of antiviral effector proteins such as ISGs and Mx proteins, thereby exerting antiviral and immunomodulatory effects^[2] In Vivo:Peginterferon alfa-2a (Ro 25-8310/000) (40 kDa; subcutaneous injection) extends the terminal elimination half-life to 15.0 h and the mean plasma residence time to 20.0 h in rats, and produces more sustained plasma exposure compared with conventional IFN alfa-2a^[1].
Peginterferon alfa-2a (40 kDa) distributes to the liver and kidneys in rats. Intact Peginterferon alfa-2a remains detectable in the blood and liver for at least 24 h after administration, and exhibits reduced renal clearance and prolonged hepatic antiviral activity^[1].